Companies: 10,795·Total market cap: $144.5T
Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

AMPHNASDAQHealthcare● Active
$19.74
+$1.04(+5.56%)
Market Cap$870394221
P/E Ratio
52W High$31.26
52W Low$16.65
Overview

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

amph · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 12 Wall Street analysts in the past 3 months

SellBuy

Hold

12 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
3
Hold
9
Sell
0
Strong Sell
0
Total: 12 · Buy rate: 25.0%

12-Month Price Target

High

$22.00

Consensus

$20.50

+3.9% upside

Low

$19.00

Median: $20.5 · Last Close: $19.74

The Amphastar Pharmaceuticals, Inc. (AMPH) analyst consensus is Hold, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month AMPH price target is $20.50, representing +3.9% upside from the current price of $19.74.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $21 (3.9%)

Consensus Target

$20.50

3.9% upside

High Target

$22

11.4%

Low Target

$19

-3.7%

Current Price

$19.74

as of today

Based on analyst price targets, the AMPH stock price prediction for the next 12 months ranges from $19 to $22. The consensus AMPH price forecast of $20.50 implies 3.9% upside from the current price of $19.74.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$19.941.03%

1-day model range: $19.77–$20.12. Peak: $20.12 (+1.03%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$15-22.1%
2028$14-31.6%
2029$13-36.2%
2030$12-38.5%
2031-39.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

43%0%57%
6Buy
0Neutral
8Sell
RSI (14)77.1Overbought
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · AMPH · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$18.69BUY
MA 10$18.79BUY
MA 20$18.33BUY
MA 50$20.14SELL
MA 100$22.29SELL
MA 200$24.50SELL
Current $AMPH · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$18.94BUY
EMA 10$18.80BUY
EMA 20$19.03BUY
EMA 50$20.09SELL
EMA 100$21.61SELL
EMA 200$23.82SELL
Current $AMPH · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-06-03
Maintains
Equal WeightEqual Weight
Wells Fargo2026-05-14
Downgrade ↓
OverweightEqual Weight
Piper Sandler2026-05-11
Maintains
NeutralNeutral
Needham2026-05-08
Downgrade ↓
BuyHold
Jefferies2026-04-21
Downgrade ↓
BuyHold
Barclays2026-04-08
Maintains
Equal WeightEqual Weight
Needham2026-02-27
Maintains
BuyBuy
Wells Fargo2026-02-27
Maintains
OverweightOverweight
Needham2025-11-07
Maintains
BuyBuy
Needham2025-10-22
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Amphastar Pharmaceuticals, Inc. (AMPH) stock. Of the recent 48 rating actions, 3 were upgrades and 11 were downgrades. 12 analysts currently cover AMPH.

Analyst Recommendation Trends

Buy ratings101
Hold ratings01↑ +1
Sell ratings00

AMPH analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$747M

↓ 7.7% YoY

Revenue Next Year

$788M

↑ 5.6% YoY

EPS This Year

$2.68

EPS Next Year

$3.14

↑ 17.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AMPH EPS of $2.68 for the current fiscal year, based on estimates from 3 analysts. The AMPH revenue forecast is $747M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AMPH stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AMPH price target is $20.50 (+3.9% upside), with an analyst consensus of Hold.

The AMPH short-term stock prediction for tomorrow is $19.94 (+1.03%). The AMPH stock price prediction for 2027 estimates an average of $15. The AMPH stock prediction for 2030 projects a range of $11–$13.

Amphastar Pharmaceuticals, Inc. trades on NASDAQ under the ticker AMPH. The AMPH stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 25% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AMPH forecast · 8 questions

According to 12 Wall Street analysts, the average 12-month AMPH price target is $20.50, with a high forecast of $22.00 and a low of $19.00. The median price target is shown in the chart above when available. This implies +3.9% potential upside from the current price of $19.74.

AMPH price targetWhat is AMPH price targetAMPH analyst price targetAMPH 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.